CASP8 and neoplasm: Concomitant methylation status analysis of GATA6 and CASP8 showed the lowest median survival in a group of patients with both methylated genes in a tumor (median survival – 4.9 months), and the difference was significant as compared with patients whose tumors had methylated GATA6 and unmethylated CASP8 (median survival – 9.7 months; log-rank test, P = 0.03) (Figure 3C).